DE60319714D1 - Agonisten des cannabinoidrezeptors - Google Patents

Agonisten des cannabinoidrezeptors

Info

Publication number
DE60319714D1
DE60319714D1 DE60319714T DE60319714T DE60319714D1 DE 60319714 D1 DE60319714 D1 DE 60319714D1 DE 60319714 T DE60319714 T DE 60319714T DE 60319714 T DE60319714 T DE 60319714T DE 60319714 D1 DE60319714 D1 DE 60319714D1
Authority
DE
Germany
Prior art keywords
agonists
cannabinoid receptor
cannabinoid
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60319714T
Other languages
English (en)
Other versions
DE60319714T2 (de
Inventor
Joseph A Kozlowski
Bandarpalle B Shankar
Neng-Yang Shih
Ling Tong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE60319714D1 publication Critical patent/DE60319714D1/de
Application granted granted Critical
Publication of DE60319714T2 publication Critical patent/DE60319714T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
DE60319714T 2002-06-19 2003-06-17 Agonisten des cannabinoidrezeptors Expired - Lifetime DE60319714T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38978802P 2002-06-19 2002-06-19
US389788P 2002-06-19
PCT/US2003/019245 WO2004000807A1 (en) 2002-06-19 2003-06-17 Cannabinoid receptor agonists

Publications (2)

Publication Number Publication Date
DE60319714D1 true DE60319714D1 (de) 2008-04-24
DE60319714T2 DE60319714T2 (de) 2009-04-02

Family

ID=30000466

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319714T Expired - Lifetime DE60319714T2 (de) 2002-06-19 2003-06-17 Agonisten des cannabinoidrezeptors

Country Status (14)

Country Link
US (1) US7217732B2 (de)
EP (1) EP1539693B9 (de)
JP (1) JP2005533809A (de)
CN (1) CN1662496A (de)
AR (1) AR039698A1 (de)
AT (1) ATE388937T1 (de)
AU (1) AU2003243637A1 (de)
CA (1) CA2487346A1 (de)
DE (1) DE60319714T2 (de)
ES (1) ES2303599T3 (de)
MX (1) MXPA04012704A (de)
PE (1) PE20040574A1 (de)
TW (1) TW200405892A (de)
WO (1) WO2004000807A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
WO2003024448A2 (en) * 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
ATE496901T1 (de) * 2003-05-20 2011-02-15 Univ Tennessee Res Foundation Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung
JPWO2005016351A1 (ja) * 2003-08-18 2006-10-12 塩野義製薬株式会社 カンナビノイド受容体アゴニストの新規用途
US20070032483A1 (en) * 2003-09-11 2007-02-08 Julia Greil Process for the production of mycophenolate mofetil
WO2005030704A1 (en) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
AU2004303461B2 (en) * 2003-12-23 2011-04-28 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
CN1993125A (zh) * 2004-05-21 2007-07-04 Uab研究基金会 涉及嘧啶合成抑制剂的组合物和方法
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
CA2641859A1 (en) * 2006-02-09 2007-08-16 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
KR101495611B1 (ko) * 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
CA2657247A1 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
JP5030114B2 (ja) 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体をモジュレートする化合物
US8940900B2 (en) 2007-02-28 2015-01-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
EP2217565B1 (de) 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Cb2 rezeptor-modulierende verbindungen
WO2010005782A1 (en) 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
JP5453437B2 (ja) 2008-09-25 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節するスルホニル化合物
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2480544A1 (de) 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Verbindungen für selektive cb2-rezeptormodulation
EP2523936A1 (de) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Cb2 rezeptor-modulierende verbindungen
JP5855095B2 (ja) 2010-06-07 2016-02-09 ノボメディックス，エルエルシーＮｏｖｏｍｅｄｉｘ，Ｌｌｃ フラニル化合物およびその使用
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
EP2803668A1 (de) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
CN112552200B (zh) * 2019-09-10 2024-03-12 烟台药物研究所 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法
CN111909053B (zh) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 基于二芳胺单元的酰胺类衍生物及其制备方法和应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2419199A (en) * 1945-02-09 1947-04-22 Parke Davis & Co Quinoline compounds and process of making same
JPS5630893A (en) * 1979-08-24 1981-03-28 Sumitomo Chem Co Ltd Recording paper
US4466965A (en) 1982-07-26 1984-08-21 American Hospital Supply Corporation Phthalazine compounds, compositions and use
US4567184A (en) 1982-12-01 1986-01-28 Usv Pharmaceutical Corporation Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies
NO174506B (no) 1984-10-30 1994-02-07 Usv Pharma Corp Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
JPH0647578B2 (ja) * 1986-10-08 1994-06-22 宇部興産株式会社 アラルキルアミノピリミジン誘導体、その製造法並びに該誘導体を有効成分とする殺虫剤、殺ダニ剤及び殺菌剤
JPH0625159B2 (ja) * 1987-09-10 1994-04-06 宇部興産株式会社 アラルキルアミノピリミジン誘導体、その製造法並びに該誘導体を有効成分とする殺虫剤、殺ダニ剤及び殺菌剤
DE3766475D1 (de) 1986-11-03 1991-01-10 Merck & Co Inc 4-(benzoyl)thiophen(oder furan)-sulfonamid und derivate fuer die aeusserliche behandlung von erhoehtem augeninnendruck.
JP2531989B2 (ja) * 1988-09-14 1996-09-04 吉富製薬株式会社 ピリジン化合物
JP2861104B2 (ja) * 1988-10-14 1999-02-24 三菱化学株式会社 ピラゾールアミド類およびこれを有効成分とする殺虫、殺ダニ剤
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
KR920701167A (ko) 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
US5332820A (en) 1991-05-20 1994-07-26 E. I. Du Pont De Nemours And Company Dibenzobicyclo(2.2.2) octane angiotensin II antagonists
US5506227A (en) 1992-04-13 1996-04-09 Merck Frosst Canada, Inc. Pyridine-substituted benzyl alcohols as leukotriene antagonists
JPH0672979A (ja) 1992-06-08 1994-03-15 Hiroyoshi Hidaka アミノベンジル誘導体
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
AU4949293A (en) * 1992-08-28 1994-03-29 Ciba-Geigy Ag Indazole derivatives
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
EP1195372A1 (de) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
IT1271266B (it) 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
EA000304B1 (ru) 1995-02-02 1999-04-29 Смитклайн Бичам Плс Производные индола как антагонисты рецептора 5-ht
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
GB9508748D0 (en) * 1995-04-28 1995-06-14 British Biotech Pharm Benzimidazole derivatives
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
DK0848703T3 (da) 1995-07-21 2001-01-02 Nycomed Austria Gmbh Derivater af benzosulfonamider som inhibitorer for enzymet cyclooxygenase II
DE19533644A1 (de) 1995-09-12 1997-03-13 Nycomed Arzneimittel Gmbh Neue Benzolsulfonamide
FR2742148B1 (fr) 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
AU1618697A (en) 1996-02-06 1997-08-28 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
WO1998010763A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Thrombin inhibitors
JP2001508799A (ja) 1997-01-21 2001-07-03 スミスクライン・ビーチャム・コーポレイション 新規カンナビノイド受容体モジュレータ
ATA16597A (de) 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
JP2001516361A (ja) 1997-03-18 2001-09-25 スミスクライン・ビーチャム・コーポレイション 新規カンナビノイド受容体作動薬
DE19718181A1 (de) * 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
WO1999021851A1 (fr) 1997-10-24 1999-05-06 Nissan Chemical Industries, Ltd. Composes de sulfamyle et bactericide agricole ou horticole
WO1999026612A1 (en) 1997-11-21 1999-06-03 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
WO1999042461A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
PL343249A1 (en) 1998-03-26 2001-07-30 Shionogi & Co Indole derivatives with antiviral activity
PL345713A1 (en) 1998-07-28 2002-01-02 Smithkline Beecham Corp Substituted anilide compounds and methods
MXPA01011173A (es) * 1999-05-06 2002-04-24 Neurogen Corp 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba.
EP2014285B1 (de) 1999-11-26 2010-05-05 Shionogi&Co., Ltd. NPYY5-Antagonisten
EP1237888B1 (de) 1999-12-15 2006-09-13 Bristol-Myers Squibb Company Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
US20030232789A1 (en) 1999-12-15 2003-12-18 Allen Darin Arthur Salicylamides as serine protease and factor xa inhibitors
EP1259485B1 (de) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. Benzamide und ähnliche inhibitoren vom faktor xa
US6498151B2 (en) 2000-03-22 2002-12-24 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
WO2001074762A2 (en) 2000-04-03 2001-10-11 Phycogen, Inc. Arylsulfates and their use as enhancers or inhibitors of bioadhesion to surfaces
AU2001241142B2 (en) 2000-04-28 2005-09-22 Tanabe Seiyaku Co., Ltd. Cyclic compounds
CN1251671C (zh) 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
EP1387831A1 (de) * 2001-05-09 2004-02-11 Bayer CropScience AG Substituierte arylketone
PL369952A1 (en) 2001-11-14 2005-05-02 Schering Corporation Cannabinoid receptor ligands
GB2384313A (en) * 2002-01-18 2003-07-23 Qinetiq Ltd An attitude sensor
AR040126A1 (es) * 2002-05-29 2005-03-16 Glaxo Group Ltd Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento

Also Published As

Publication number Publication date
CA2487346A1 (en) 2003-12-31
TW200405892A (en) 2004-04-16
WO2004000807A1 (en) 2003-12-31
AU2003243637A1 (en) 2004-01-06
EP1539693B9 (de) 2008-10-08
ATE388937T1 (de) 2008-03-15
JP2005533809A (ja) 2005-11-10
CN1662496A (zh) 2005-08-31
PE20040574A1 (es) 2004-09-08
EP1539693A1 (de) 2005-06-15
ES2303599T3 (es) 2008-08-16
US20040044051A1 (en) 2004-03-04
EP1539693B1 (de) 2008-03-12
AR039698A1 (es) 2005-03-09
US7217732B2 (en) 2007-05-15
MXPA04012704A (es) 2005-03-23
DE60319714T2 (de) 2009-04-02

Similar Documents

Publication Publication Date Title
DE60319714D1 (de) Agonisten des cannabinoidrezeptors
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
DE60325025D1 (de) Modulatoren des vanilloidrezeptors
DE60308850D1 (de) Pyridinoylpiperidine als 5-ht1f agonisten
IS7607A (is) Ný útskipt indól
IS8032A (is) Kannabinóíð viðtakabindlar og notkun þeirra
NL1025148A1 (nl) Benzamideremmers van de P2X7-receptor.
IS7667A (is) Nýjar bensimídazólafleiður
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
DE60317365D1 (de) Substituierte 4-alkoxyoxazol derivate als ppar agonisten
FI20020282A0 (fi) Valaisin
NO20043907L (no) Partielle og fullstendige agonister av A1-adenosinreseptorer
DE60328978D1 (de) Isochinolinderivate als mao-b inhibitoren
NO20041107L (no) Muskarine agonister
NO20034497L (no) Somatostatin agonister
NO20043396L (no) Kortikotropinfrigjorende faktorreseptor 2-agonister
DE602004007387D1 (de) 5-substituierte chinazolinonderivate
DE60324018D1 (de) Agonisten
DE60236403D1 (de) Tourbillonmechanismus
DE60328033D1 (de) Cannabinoid-rezeptorliganden
NO20023047A (no) Kompenseringsanordning
ATE491683T1 (de) Muskarine agonisten
DE602004031346D1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
DE50310191D1 (de) Zwischenspeicher
DE60301017D1 (de) Tastkopfhalterung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition